Adial Pharmaceuticals, Inc. (NASDAQ: NASDAQ:ADIL), a clinical-stage biopharmaceutical company, has filed a patent application for AD04, a therapeutic agent aimed at treating Alcohol Use Disorder (AUD) in patients with heavy drinking patterns.
The new patent application comes after the company engaged with new patent counsel to enhance its intellectual property portfolio. If granted, the patent is expected to extend protection for the company's core assets until at least 2044.
The company claims that AD04, a serotonin-3 receptor antagonist, is currently under investigation in a pharmacokinetics study and has shown promise in reducing heavy drinking with no significant safety or tolerability concerns.
AD04 was the subject of the ONWARD pivotal Phase 3 clinical trial, which targeted genotypes identified using the company's companion diagnostic genetic test. The trial results indicated a potential reduction in heavy drinking among patients, said the company.
Beyond AUD, AD04 is also being considered for the treatment of other addictive disorders, including Opioid Use Disorder, gambling, and obesity.
Cary Claiborne, President and CEO of Adial, expressed optimism about the patent application's role in advancing the AD04 program and protecting the company's interests long-term.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.